Enhanced glycemic control using Ad36E4orf1 and AKT1 inhibitor
AssigneeBoard of Supervisors of Louisiana State University and Agricultural and Mechanical College
InventorsNikhil Dhurandhar, Rashmi Krishnapuram
Life of this patent
Estimating the term…
Abstract
This invention generally relates to methods for improving glycemic control by administering an Ad36 composition and an AKT1 inhibitor.
Claims6
A method of improving glycemic control in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of an Adenovirus-36 (Ad36) E4orf1 protein or a functional variant thereof and a selective AKT1 inhibitor, wherein glycemic control is improved without substantial increase in adipogenesis.
A method of increasing insulin sensitivity in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of an Adenovirus-36 (Ad36) E4orf1 protein or a functional variant thereof and a selective AKT1 inhibitor, wherein insulin sensitivity is increased without substantial increase in adipogenesis.
A method of treating hyperglycemia or insulin resistance in the individual, comprising administering to an individual in need thereof a therapeutically effective amount of an Adenovirus-36 (Ad36) E4orf1 protein or a functional variant thereof and a selective AKT1 inhibitor, wherein the individual's symptoms improve without substantial increase in adipogenesis.
Dependencies are inferred from the claim text.